Digital PCR and Real-Time PCR Market to Reach US$ 17.54 Billion by 2031, Advancing at a 9.1% CAGR from 2025–2031

United States of America – December 29, 2025 – According to The Insight Partners, the digital PCR and real-time PCR market size is projected to reach US$ 17.54 billion by 2031 from US$ 9.55 billion in 2024. The market is estimated to register a CAGR of 9.1% during 2025–2031. The digital PCR and real-time PCR market is entering a pivotal growth phase as healthcare systems, research institutions, and biopharma companies intensify their focus on precision diagnostics, infectious disease management, and advanced genomics. These technologies are steadily transitioning from specialized tools in high-end laboratories to essential platforms in mainstream clinical and translational settings worldwide.​

Get a Sample Copy At - https://www.theinsightpartners.com/sample/TIPRE00018009/

Evolving Role in Patient-Centric Healthcare

Digital PCR (dPCR) and real-time PCR (qPCR) are now at the heart of many diagnostic and monitoring workflows, helping clinicians and scientists make faster, more confident decisions. From identifying infectious agents in critical care units to tracking minimal residual disease in oncology, PCR platforms are enabling earlier interventions and more personalized treatment strategies.​

In recent years, healthcare providers have placed greater emphasis on high-sensitivity assays that can detect low-abundance targets, genetic variants, and viral loads with exceptional accuracy. This has accelerated the adoption of both dPCR, known for its absolute quantification, and qPCR, valued for its real-time monitoring and versatility across a broad range of applications.​

Market Drivers and Updated Industry Developments

Several structural trends are shaping the outlook for the digital PCR and real-time PCR market through 2031.​

Key market drivers include:

• Rising burden of infectious and genetic diseases, fueling demand for highly sensitive molecular diagnostics.​
• Expansion of precision medicine, particularly in oncology, rare diseases, and reproductive health, where quantitative molecular assays are fundamental.​
• Growing adoption of PCR-based solutions in environmental testing, food safety, agricultural biotechnology, and forensic science.​
• Increased funding for genomics and translational research across North America, Europe, and Asia Pacific.​

Recent industry news underscores this momentum:

• QIAGEN NV has expanded its digital PCR offering for cell and gene therapy development, including new assay design services and viral vector quantification solutions, aimed at supporting biopharma customers in standardizing advanced therapies.​
• Multiple vendors are integrating AI and machine learning into PCR workflows to enhance assay optimization, reduce error rates, and improve analysis of complex datasets, particularly in oncology and forensic applications.​
• Real-time PCR systems continue to evolve with multiplexing capabilities, higher throughput, and improved software, supporting laboratories as they scale testing volumes and move toward more automated, connected platforms.​

Product, Application, Type, and End-User Landscape

Across product and service categories, reagents and consumables remain the backbone of recurring revenue, supported by continuous test utilization and new assay development. Instruments are seeing robust upgrades as labs replace legacy platforms with advanced digital and real-time systems that offer better sensitivity, workflow integration, and connectivity. Software and services are becoming increasingly important as users seek data management, cloud connectivity, and analytics to handle larger volumes of quantitative results.​

On the application front, the market is deeply embedded in infectious disease testing, including respiratory pathogens, emerging viral threats, and hospital-acquired infections. Oncology testing is another major growth arena, where PCR supports liquid biopsy, minimal residual disease monitoring, companion diagnostics, and stratification of patients based on molecular signatures. Blood screening, transplant diagnostics, and broader genetic testing round out a diverse portfolio of clinical and research uses.​

From an end-user perspective, hospitals and diagnostic centers account for a substantial portion of PCR testing volumes, driven by routine diagnostics and acute care needs. Research laboratories and academic institutes rely heavily on PCR for basic and translational research, while pharmaceutical and biotechnology companies increasingly use digital PCR and qPCR for drug development, cell and gene therapy programs, quality control, and biomarker validation. Clinical research organizations and forensic laboratories further expand the addressable market with specialized, high-precision testing requirements.​

Global and Regional Market Outlook to 2031

The digital PCR and real-time PCR market is global in scope, with adoption patterns that reflect healthcare priorities, regulatory environments, and investment capacity across regions. North America currently leads in terms of technology penetration, supported by strong healthcare infrastructure, substantial R&D spending, and early adoption of cutting-edge molecular diagnostic platforms. Europe follows closely, with a mature regulatory landscape and a strong installed base of molecular testing systems across both public and private laboratories.​

Asia Pacific is emerging as the fastest-growing region, supported by expanding healthcare coverage, rising laboratory capacity, and government-backed initiatives in genomics, infectious disease control, and oncology. Countries in the Middle East, Latin America, and parts of Africa are also accelerating investment in molecular diagnostics, often focusing on capacity-building programs and partnerships with global manufacturers to expand access to advanced PCR-based testing.​

Market size, share, trends, analysis, and forecast (qualitative highlights to 2031)

• Market size:
• Continued expansion in overall demand for digital PCR and real-time PCR platforms and reagents across clinical, research, and industrial settings, with strong adoption in hospitals, diagnostic centers, and biopharma manufacturing by 2031.​
• Market share:
• Robust presence of leading multinational players alongside specialized regional vendors, with high brand visibility for established instrument and reagent portfolios in core applications such as infectious disease and oncology.​
• Key trends:
• Shift toward AI-enabled assay optimization and data analysis.​
• Rising utilization of digital PCR for absolute quantification in applications where sensitivity and precision are critical.​
• Integration of PCR systems with automated sample preparation, laboratory information systems, and cloud-based reporting.​
• Market analysis:
• Steady transition from purely research-oriented deployments toward a more balanced mix of clinical diagnostics, translational research, and industrial quality control, supported by favorable reimbursement in select markets.​
• Focus on assay menus that address high-burden disease areas and enable laboratories to consolidate testing on fewer, more flexible platforms.​
• Forecast to 2031:
• Sustained growth expected as healthcare systems prioritize molecular diagnostics for early detection, surveillance, and personalized medicine, with notable acceleration in emerging economies and specialized high-value segments such as oncology and cell and gene therapies.​

Purchasing This Report? Click Here At - https://www.theinsightpartners.com/buy/TIPRE00018009/

If you have any special requirements about this Digital PCR and Real-Time PCR Market report, please let us know and we can provide custom report.

Leading Companies and Competitive Landscape

The competitive landscape features a mix of long-established diagnostics leaders and specialized molecular technology providers. Prominent companies active in the digital PCR and real-time PCR market include QIAGEN NV, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Takara Bio Inc, Agilent Technologies Inc, bioMérieux SA, Danaher Corp, Abbott Laboratories, and other innovative players such as Countable Labs and regional specialists.​

These manufacturers are investing in new chemistries, more intuitive software, and integrated workflows to make PCR technology more accessible to laboratories of all sizes. Strategic collaborations, acquisitions, and geographic expansion are expected to remain central to competitive strategy as companies seek to deepen their presence in high-growth regions and niche application areas.​

Organizations across the value chain—from hospitals and national reference laboratories to agile start-ups—are leveraging digital PCR and real-time PCR to deliver more precise, timely, and actionable insights for patients, researchers, and public health agencies worldwide.

Related Reports

• dPCR and qPCR Market Analysis, Size, and Share by 2030
• PCR Technologies Market Developments and Forecast by 2030
• Polymerase Chain Reaction Technologies Market Overview, Growth, and Development 2031
• Digital PCR (dPCR) Market Size, Share, and Analysis by 2031
• Cartridges for RT-PCR Automatic Systems Market Analysis and Forecast by Size, Share, Growth, Trends 2031

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.

Contact Us:

If you have any queries about this report or if you would like further information, please get in touch with us:

Contact Person: Ankit Mathur

E-mail: ankit.mathur@theinsightpartners.com

Phone: +1-646-491-9876

Also Available in: 日本 | 한국어 | Français | لعربية< | 中文 | Italiano | Español | Deutsch